Cantor Fitzgerald Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $7
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7
X4 Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)
X4 Pharmaceuticals' Earnings Call: Progress Amid Challenges
X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript Summary
X4 Pharmaceuticals Targets $1-2B U.S. Market for Mavorixafor in Chronic Neutropenia
X4 Pharmaceuticals Shares Are Trading Lower. The Company Reported Q1 Financial Results.
10-Q: Q1 2025 Earnings Report
Express News | X4 Pharmaceuticals: Full Enrollment on Track for 3Q or 4Q 2025 and Top-Line Data in 2H 2026
8-K: X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Express News | X4 Pharmaceuticals Inc - Announces Strategic Restructuring to Focus on Mavorixafor
Press Release: X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
X4 Pharmaceuticals 1Q EPS 4c >XFOR
Express News | X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Earnings Scheduled For May 1, 2025
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) Is Surging in 2025
X4 Pharmaceuticals Management to Meet With Cantor Fitzgerald